Based on the Iron (Fe) and Atherosclerosis Study (FeAST).ppt

Based on the Iron (Fe) and Atherosclerosis Study (FeAST).ppt

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
Based on the Iron (Fe) and Atherosclerosis Study (FeAST).ppt

Based on the Iron (Fe) and Atherosclerosis Study (FeAST) FeAST Trial: Background Accumulation of iron in excess of physiologic requirements has been implicated in risk of cardiovascular disease because of increased iron-catalyzed free radical-mediated oxidative stress. The objective of this study was to test the hypothesis that reducing body iron stores through phlebotomy will influence outcomes in a cohort of patients with symptomatic peripheral arterial disease (PAD). FeAST Trial: Primary and Secondary Outcome Events FeAST Trial: Kaplan-Meir Analysis of Primary Endpoint (All-Cause Mortality) FeAST Trial: Kaplan-Meir Analysis of Secondary Endpoint (Death Plus Nonfatal MI, or Stroke) FeAST Trial: Limitations Because of lower than expected accrual, the study was underpowered overall and particularly underpowered to definitively assess outcomes in younger patients and smokers. This study was single-blinded, and primary and secondary endpoints were adjudicated by a committee external to the study; nonetheless, concerns remain about possible bias, particularly in subgroup analyses. FeAST Trial: Limitations (cont.) Patients with very high ferritin levels were excluded from the study, and the efficacy of iron reduction in individuals with extreme levels of iron stores is unknown. FeAST Trial: Summary Preplanned analyses of the primary (all-cause mortality) and the secondary (death plus nonfatal MI and stroke) endpoints performed on the entire study cohort showed no effect of iron reduction. However, there was a significant interaction with age (1of 5 prespecified biological stratifying factors), suggesting that a beneficial effect might exist in younger patients, and observation that coincides with findings of others. FeAST Trial: Summary (cont.) The FeAST data show that it should be possible to test definitively whether controlling iron levels may reduce disease risk and additional research is needed to further define ferrotoxic diseases, stratifying risk reduct

文档评论(0)

gsgtshb + 关注
实名认证
内容提供者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档